Experimental Therapeutics Program
Overview | Leaders | Research | Publications | Resources | Members
Selected Publications
2003
Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. J Immunol Methods 2003;279(1-2):183-192.
Hwang JJ, Eisenberg SG, Marshall JL. Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology (Williston Park) 2003;17(9 Suppl 8):37-43.
Hwang JJ, Marshall JL, Rizvi N. Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin. Oncology (Williston Park) 2003;17(5 Suppl 5):46-51.
Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, III, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 2003;21(13):2589-2596.
Kozikowski AP, Nowak I, Petukhov PA, Etcheberrigaray R, Mohamed A, Tan M, Lewin N, Hennings H, Pearce LL, and Blumberg PM. New amide-bearing benzolactam-based protein kinase c modulators induce enhanced secretion of the amyloi precursor protein metabolite sAPPalpha. J Med Chem 2003;46:364-373.
Kozikowski AP, Sun H, Brognard J, and Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003;125:1144-1145.
Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003;99(1):55-77.
Rait AS, Pirollo KF, Ulick D, Cullen K, Chang EH. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann N Y Acad Sci 2003;1002:78-89.
Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21(11):2059-2069.
Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, and Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003;63:312-8.
Toretsky JA, Jenson J, Sun CC, Eskenazi AE, Campbell A, Hunger SP, Caires A, Frantz C, Hill JL, and Stamberg J. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol 2003;26:300-6.
Toretsky JA, Everly EM, Padilla-Nash HM, Chen A, Abruzzo LV, Eskenazi AE, Frantz C, Ried T, and Stamberg J. Novel translocation in acute megakaryoblastic leukemia (AML-M7). J Pediatr Hematol Oncol 2003;25:396-402.
Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, and Toretsky JA. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:2334-42.
Venook AP, Enders KC, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14(12):1783-1790.
Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, Bromberg JF, Lamberti C, Verma U, Gaynor RB, Byers SW, and Pestell RG. IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol BioI Cell 2003;14:585-599.
Cheshire WP Jr, Pellegrino ED, Bevington LK, Mitchell CB, Jones NL, FitzGerald KT, Koop CE, and Kilner JF. Stem cell research: why medicine should reject human cloning. Mayo Clin Proc 2003;78:1010-1018.
Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, and Lisanti MP. Caveolin-l null mice develop cardiac hypertrophy with hyperactivation ofp42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 2003;284:C457474.
D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russell RG, Muller WJ, White M, Negassa A, Lee HW, DePinho RA, and Pestell RG. The role of Ink4a/Arfin ErbB2 mammary gland tumorigenesis. Cancer Res 2003;63:3395-3402.
DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, and Freeman W. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003;22:7781-7795.
Hayes TM, Underhill CR, Clarke K, and Tattersall MH. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2003;178:412-413.
Kagan BL, Henke RT, Cabal-Manzano R, Stoica GE, Nguyen Q, Wellstein A, Riegel AT. Complex regulation of the fibroblast growth factor-binding protein in MDA- MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Cancer Res 2003;63(7):1696-1705.
Kitlinska J, Lee EW, Li L, Pons J, Estes L, and Zukowska Z. Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling. Adv Exp Med BioI 2003;524:215-222.
Lee EW, Grant DS, Movafagh S, and Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 2003;24:99-106.
Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant DS, and Zukowska Z. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003;Ill:1853-1862.
Li L, Lee EW, Ji H, and Zukowska Z. Neuropeptide Y-induced acceleration ofpostangioplasty occlusion ofrat carotid artery. Arterioscler Thromb Vasc BioI 2003;23:1204-1210.
Pons J, Kitlinska J, Ji H, Lee EW, and Zukowska Z. Mitogenic actions ofneuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Phannacol 2003;81:177-185.
Ray R, Cabal-Manzano R, Moser AR, Waldman T, Zipper LM, Aigner A, Byers SW, Riegel AT, and Wellstein A. Up-regulation of fibroblast growth factor-binding protein, by betacatenin during colon carcinogenesis. Cancer Res 2003;63:8085-8089.
Russell RJ, Murray JB, Lentzen G, Haddad J, and Mobashery S. The complex ofa designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chern Soc 2003;125:3410-3411.
Shah S, Hecht A, Pestell R, and Byers SW. Trans-repression of beta-catenin activity by nuclear receptors. J BioI Chern 2003;278:48137-48145.
Shore SM, Byers SA, Maury W, and Price DH. Identification of a novel isoform ofCdk9. Gene 2003;307:175-182.
Song LN, Herrell R, Byers S, Shah S, Wilson EM, and Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell BioI 2003;23:1674-1687.
Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, and Stoica A. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-KJAkt pathway. Oncogene 2003;22:7998-8011.
Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003;17(5):818-830.
Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB, Stoica A. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22(14):2073-2087.
Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H, Pei XF, Chen J, Yang S, Underhill CB, Liu L, Liekens L, Merregaert J, and Zhang L. Extracellular matrix protein 1 (ECM1) is overexpressed in malignant epithelial tumors. Cancer Lett 2003;200:57-67.
Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, and Pestell RG. DACHI inhibits transfOIming growth factor-beta signaling through binding Smad4. J BioI Chern 2003;278:51673-51684.
Xu XM, Chen Y, Chen J, Yang S, Gao F, Underhill CB, Creswell K, and Zhang LA. Peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res 2003;63:5685-5690.
Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, and Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65-72.
Zhou X, Quann E, and Gallicano GI. Differentiation of nonbeating embryonic stem cells into beating cardiomyocytes is dependent on downregulation ofPKC beta and zeta in concert with upregulation ofPKC epsilon. Dev BioI 2003;255:407-422.
Zukowska Z, Grant DS, and Lee EW. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 2003;13:86-92.
Zukowska Z, Pons J, Lee EW, and Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Phannacol 2003;81:89-94.
